View in EDS HTML Full Text PDF Full Text

Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study.

Saved in:

Bibliographic Details
Title:	Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study.
Authors:	Moliterno DJ (AUTHOR), Yakubov SJ (AUTHOR), DiBattiste PM (AUTHOR), Herrmann HC (AUTHOR), Stone GW (AUTHOR), Macaya C (AUTHOR), Neumann F (AUTHOR), Ardissino D (AUTHOR), Bassand J (AUTHOR), Borzi L (AUTHOR), Yeung AC (AUTHOR), Harris KA (AUTHOR), Demopoulos LA (AUTHOR), Topol EJ (AUTHOR), TARGET Investigators (CORPORATE AUTHOR), Moliterno, David J (AUTHOR), Yakubov, Steven J (AUTHOR), DiBattiste, Peter M (AUTHOR), Herrmann, Howard C (AUTHOR), Stone, Gregg W (AUTHOR)
Source:	Lancet. 8/3/2002, Vol. 360 Issue 9330, p355-360. 6p.
Abstract:	Background: Two placebo-controlled trials testing intravenous platelet glycoprotein IIb/IIIa antagonists in the setting of percutaneous coronary revascularisation with intracoronary stents have shown a durable reduction in ischaemic events to 6 months. These trials differed regarding their patient population, IIb/IIIa inhibitor, and reported extent of benefit. Whether a small-molecule agent affecting only the IIb/IIIa receptor would provide a similar outcome for ischaemic events and clinical restenosis at 6 months when directly compared with a monoclonal antibody known to affect several integrin receptors is unknown.Methods: In 18 countries at 149 hospitals, 4809 patients undergoing elective or urgent stent implantation were randomly assigned a bolus and infusion of tirofiban or abciximab. Patients were followed for 6 months for the occurrence of death, myocardial infarction, and any target-vessel revascularisation. The results at 30 days have been reported previously.Findings: At 6 months the composite endpoint of death, myocardial infarction, and target-vessel revascularisation occurred in 356 (14.8%) patients who received tirofiban and 345 (14.3%) patients who received abciximab (hazard ratio 1.04, 95% CI 0.90-1.21; p=0.591). The rates for the individual endpoints were 191 (8.0%) versus 159 (6.6%) for myocardial infarction (hazard ratio 1.21, 95% CI 0.98-1.50; p=0.074), 26 (1.1%) versus 25 (1.0%) for death (1.04, 0.60-1.80; p=0.893), and 194 (8.1%) versus 208 (8.6%) for target-vessel revascularisation (0.93, 0.77-1.14; p=0.495).Interpretation: At 6 months, tirofiban provided a similar level of overall protection to abciximab against the composite of death, myocardial infarction, and any target-vessel revascularisation. [ABSTRACT FROM AUTHOR]
	Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	Psychology and Behavioral Sciences Collection
Full text is not displayed to guests. Login for full access.

Be the first to leave a comment!